13F Holdings
中文EN

MAIA MAIA Biotechnology, Inc.

Pharmaceutical Preparations · NYSE · SEC CIK 1878313 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-12.4%
TTM EPS YoY36.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-341.5%
ROA-148.3%
ROIC (approx.)-296.5%
Asset turnover—

Leverage & solvency

Liabilities / assets33.6%
Debt / equity0.00x
Current ratio3.41x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.01x
Accruals ratio1.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY2023*2023-12-31FY2022*2022-12-31FY2021*2021-12-31
Income statement
Revenue—$0$0$0—
R&D expense$453,745$10.01M$11.11M$8.93M$3.50M
SG&A expense$9.72M$6.95M$9.07M$6.14M$4.29M
Operating income-$24.27M-$16.96M-$20.18M-$16.18M-$7.79M
Interest expense—$57$6,863$6,967$827,539
Pretax income-$22.39M-$23.25M-$19.80M-$15.80M-$12.60M
Income tax$2,000$2,000———
Net income-$22.40M-$23.25M-$19.77M-$15.77M-$12.50M
EPS (basic)-0.70-1.05-1.49-1.75-2.37
EPS (diluted)-0.70-1.05-1.49-1.75-2.37
Weighted avg. shares (diluted)32.11M22.20M13.26M9.28M5.28M
Balance sheet
Cash & equivalents$0$0$7.15M$10.95M$10.57M
Current assets$9.70M$10.15M$7.56M$11.81M$10.67M
Total assets$9.70M$10.16M$7.57M$12.02M$11.33M
Current liabilities$5.84M$3.83M$4.94M$3.27M$2.15M
Total liabilities$7.33M$6.52M$7.09M$3.51M$2.15M
Shareholders' equity$2.38M$3.63M$477,511$8.51M$9.18M
Shares outstanding38.62M26.16M16.99M10.96M7.58M
Cash flow statement
Operating cash flow-$18.84M-$15.70M-$13.07M-$12.10M-$4.12M
Financing cash flow$17.91M$18.18M$9.27M$12.48M$14.03M
Stock-based compensation$2.63M$1.91M$3.09M$2.32M$2.72M

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.